$LENZ News

LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

TD Cowen Maintains Buy on LENZ Therapeutics, Lowers Price Target to $50

LENZ Therapeutics (LENZ) Stock Fair Value Falls After Analysts Cut VIZZ Launch Expectations

Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $5

LENZ Therapeutics: Below Cash For A Reason

LENZ Therapeutics: Still Speculative But Priced For Disasters

LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts

Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7

LENZ Therapeutics Inc (LENZ) (Q2 2026) Earnings Call Highlights: VIZZ Launch Momentum ...

LENZ Therapeutics, Inc. Q2 2026 Earnings Call Summary

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

LENZ Therapeutics Q2 Earnings Call Highlights

LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

LENZ Therapeutics Q2 EPS $(1.02) Beats $(1.06) Estimate, Sales $5.486M Beat $2.373M Estimate

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth Assumptions

HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

LENZ Therapeutics Announces Availability Of VIZZ Through Telehealth Platform